

Amendments to the Claims

This listing of claims replaces all prior versions and listings of claims in the application:

Listing of Claims:

1. (Currently amended) An isolated nucleic acid molecule encoding a humanized immunoglobulin light chain or antigen-binding fragment thereof comprising CDR1 , CDR2 and CDR3 of the light chain of murine 1D9 antibody and a human light chain framework region from the light chain of the human HF 21/28 antibody.

2. (Cancel)

3. (Currently amended) The isolated nucleic acid molecule of Claim ~~[[2]]~~ 1, wherein said humanized immunoglobulin light chain or antigen-binding fragment thereof comprises the variable region of SEQ ID NO: ~~[[9]]~~ 12, 13, 14, 15 or 107.

4. (Currently amended) The isolated nucleic acid molecule of Claim 3, wherein said nucleic acid molecule comprises the variable region coding sequence of SEQ ID NO: ~~[[95]]~~98.

5. (Currently amended) An isolated nucleic acid molecule encoding a humanized immunoglobulin heavy chain or antigen-binding fragment thereof comprising CDR1 , CDR2 and CDR3 of the heavy chain of the 1D9 antibody and a human heavy chain framework region from the heavy chain of the human 4B4'CL antibody.

6. (Cancel)

7. (Currently amended) The isolated nucleic acid molecule of Claim [[6]] 5, wherein the humanized immunoglobulin heavy chain or antigen-binding fragment thereof comprises the variable region of SEQ ID NO: [[10]] 17, 18, 19 or 20.

8. (Currently amended) The isolated nucleic acid molecule of Claim 7, wherein said nucleic acid molecule comprises the variable region coding sequence of SEQ ID NO: [[96]] 97.

9. (Currently amended) An isolated nucleic acid molecule comprising a nucleotide sequence encoding a humanized immunoglobulin light chain or antigen-binding fragment thereof, said light chain or antigen-binding fragment thereof having an amino acid sequence comprising at least ~~a functional~~ an antigen binding portion of the light chain variable region amino acid sequence of SEQ ID NO: [[9]] 12, 13, 14, 15 or 107.

10. (Currently amended) The isolated nucleic acid molecule of Claim 9 comprising the variable region coding sequence of SEQ ID NO: [[95]] 98.

11. (Currently Amended) An isolated nucleic acid molecule comprising a nucleotide sequence encoding ~~the a~~ humanized immunoglobulin heavy chain or antigen-binding fragment thereof, said heavy chain or antigen-binding fragment thereof having an amino acid sequence comprising at least ~~a functional~~ an antigen binding portion of the heavy chain variable region amino acid sequence of SEQ ID NO: [[10]] 17, 18, 19 or 20.

12. (Currently amended) The isolated nucleic acid molecule of Claim 11 comprising the variable region coding sequence of SEQ ID NO: [[96]] 97.

13. (Currently Amended) An expression vector comprising a nucleic acid molecule of claim 1 ~~fused gene encoding a humanized immunoglobulin light chain, said gene comprising a nucleotide sequence encoding CDR derived from a light chain of a nonhuman antibody having~~

~~binding specificity for CCR2 and a framework region derived from a light chain of human origin.~~

14. (Cancel)

15. (Currently Amended) [[A]] An isolated host cell comprising the expression vector of Claim 13.

16. (Currently amended) An expression vector comprising a nucleic acid molecule of claim 5 ~~fused gene encoding a humanized immunoglobulin heavy chain, said gene comprising a nucleotide sequence encoding a CDR derived from a heavy chain of a nonhuman antibody having binding specificity for CCR2 and a framework region derived from a heavy chain of human origin.~~

17. (Cancel)

18. (Currently Amended) [[A]] An isolated host cell comprising the expression vector of Claim 16.

19. (Currently Amended) [[A]] An isolated host cell comprising a first recombinant nucleic acid molecule encoding a humanized immunoglobulin light chain and a second recombinant nucleic acid molecule encoding a humanized immunoglobulin heavy chain, wherein said first nucleic acid molecule comprises a ~~nucleotide sequence encoding a CDR derived from the light chain of murine antibody ID9 and a framework region derived from a light chain of human origin~~ nucleic acid molecule of claim 1, and wherein said second nucleic acid molecule comprises a nucleic acid molecule of claim 5 ~~nucleotide sequence encoding a CDR derived from the heavy chain of murine antibody ID9 and a framework region derived from a heavy chain of human origin.~~

20. (Original) A method of preparing a humanized immunoglobulin comprising maintaining a host cell of Claim 19 under conditions appropriate for expression of a humanized immunoglobulin, whereby humanized immunoglobulin chains are expressed and a humanized immunoglobulin is produced.

21. (Original) The method of Claim 20, further comprising the step of isolating the humanized immunoglobulin.

22. (Currently amended) A fused gene encoding a humanized immunoglobulin light ~~or heavy~~ chain comprising:

a) first nucleic acid sequence encoding an antigen binding region ~~derived from murine monoclonal antibody 1D9~~ comprising CDR1 , CDR2 and CDR3 of the light chain of murine 1D9 antibody and a human light chain framework region from the light chain of the human HF 21/28 antibody; and

b) a second nucleic acid sequence encoding at least a portion of a constant region of an immunoglobulin of human origin.

23. -65. (Cancel)

66. (New) A fused gene encoding a humanized immunoglobulin heavy chain comprising:

a) first nucleic acid sequence encoding an antigen binding region comprising CDR1 , CDR2 and CDR3 of the heavy chain of murine 1D9 antibody and a human heavy chain framework region from the heavy chain of the human 4B4 'CL antibody; and

b) a second nucleic acid sequence encoding at least a portion of a constant region of an immunoglobulin of human origin.

67. (New) The isolated nucleic acid molecule of claim 1, wherein the light chain or antigen binding fragment thereof comprises the variable region of SEQ ID NO:12.

68. (New) The isolated nucleic acid molecule of claim 5, wherein the light chain or antigen binding fragment thereof comprises the variable region of SEQ ID NO:17.

69. (New) The isolated nucleic acid molecule of claim 22, wherein the first nucleic acid encodes the variable region of SEQ ID NO:12.

70. (New) The isolated nucleic acid molecule of claim 66, wherein the first nucleic acid encodes the variable region of SEQ ID NO:17.

71. (New) The expression vector of claim 13, wherein the nucleic acid molecule encodes the humanized light chain or antigen binding portion thereof of SEQ ID NO:12.

72. (New) An isolated host cell comprising the expression vector of claim 71.

73. (New) The expression vector of claim 16, wherein the nucleic acid molecule encodes the humanized heavy chain or antigen binding portion thereof of SEQ ID NO:17.

74. (New) An isolated host cell comprising the expression vector of claim 73.

75. (New) The isolated host cell of claim 19, wherein the first nucleic acid molecule encodes the humanized light chain or antigen binding portion thereof of SEQ ID NO:12.

76. (New) The isolated host cell of claim 19, wherein the second nucleic acid molecule encodes the humanized heavy chain or antigen binding portion thereof of SEQ ID NO:17.

77. (New) The isolated host cell of claim 75, wherein the second nucleic acid molecule encodes the humanized heavy chain or antigen binding portion thereof of SEQ ID NO:17.

78. (New) A method of preparing a humanized immunoglobulin comprising maintaining a host cell of any of claims 75, 76 or 77 under conditions appropriate for expression of a humanized immunoglobulin, whereby humanized immunoglobulin chains are expressed and a humanized immunoglobulin is produced.

79. (New) The method of claim 78, further comprising the step of isolating the humanized immunoglobulin.

80. (New) The isolated host cell of any one of claims 15, 18 and 19, wherein the host cell is a mammalian host cell.

81. (New) The isolated host cell of claim 80, wherein the host cell is selected from the group consisting of a COS cell, a CHO cell, a HeLa cell, and an NSO cell.

82. (New) The isolated host cell of any one of claims 72, 74, 75, 76 and 77, wherein the host cell is a mammalian host cell.

83. (New) The isolated host cell of claim 82, wherein the host cell is selected from the group consisting of a COS cell, a CHO cell, a HeLa cell, and an NSO cell.

84. (New) The expression vector of any one of claims 13, 16, 71 and 73, further comprising one or more of: a selectable marker gene, and a transcriptional control element.

85. (New) The expression vector of claim 84, wherein the vector comprises one or more selectable marker selected from the group consisting of: an ampicillin resistance gene, a neomycin resistance gene and a dihydrofolate reductase marker gene.